The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Randall Bateman M.D.
Project Title: A blood isotope labeled amyloid-beta test for Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1822
Aim 1: To determine blood Aβ isoform level relationships to CSF Aβ and amyloid PET, using archived blood samples from cross-sectional and longitudinal studies of cognitively normal, AD, and other neurodegenerative dementias.
Aim 2: We would like to explore if there are changes (perhaps diffuse plaques or biochemical changes) in the neuropathology cases that also have collected blood samples near the time of brain donation (within 1 or 2 years is best)
Aim 3: The hypothesis is that the plasma abeta42/40 will be abnormal at times when amyloid plaque (including diffuse) begins and before PET scans would detect it.
Aim 4:
Investigator: David Holtzman
Project Title: Assessment of neuritic plaque p-tau, A�42, and microgliosis in AD-associated TREM2 variant carriers
Date: December 21, 2021 at 5:02 pm
Request ID: T1419-A
Aim 1: Assess plaques assoicated tau and p-tau staining and Ab42 staining TREM2 WT and R47H/R62H carriers
Aim 2: Biochemically assess soluble and insoluble tau and p-tau levels
Aim 3:
Aim 4:
Investigator: Courtney Sutphen
Project Title: Simoa Plasma Assay for Neurofilament Light Chain (NfL)
Date: December 21, 2021 at 5:02 pm
Request ID: T1901
Aim 1: Evaluate analytical performance of the Quanterix Simoa plasma assay for NfL
Aim 2: Evaluate correspondence of plasma NfL with established CSF and imaging biomarkers of AD
Aim 3: Evaluate diagnostic performance of plasma NfL
Aim 4: Characterize the profile of longitudinal plasma NfL
Investigator: Joseph M Castellano
Project Title: Plasma protein-mediated effects of ApoE4 expression on brain in AD
Date: December 21, 2021 at 5:02 pm
Request ID: T1902
Aim 1: To investigate plasma protein differences between cognitively normal human subjects homozygous for APOE-e4 or APOE-e3 alleles using aptamer-based protein platform for ~1000 proteins to identify pathways and regulators of peripheral dysfunction impacting brain health.
Aim 2:
Aim 3:
Aim 4:
Investigator: Randall Bateman
Project Title: ApoE proteoforms in the human CNS and validation of translational ApoE pharmacodynamic markers
Date: December 21, 2021 at 5:02 pm
Request ID: T1903
Aim 1: Aim 1: Characterize ApoE truncations, fragments, and post-translational modifications found in human brain, CSF and plasma.
Aim 2: Aim 2: Target ApoE and A� kinetics in an AD animal model expressing human ApoE and human A� treated with an ApoE LDLR upregulation (clearance activator) or ASO ApoE knockdown (production inhibitor) to assess whether targeting ApoE levels changes ApoE and A� kinetics.
Aim 3:
Aim 4:
Investigator: Gregory S Day
Project Title: RT-QuIC testing in “preclinical” CJD
Date: December 21, 2021 at 5:02 pm
Request ID: T1904
Aim 1: To determine the sensitivity of RT-QuIC testing in CSF obtained from research participants who were eventually diagnosed with sporadic CJD.
Aim 2:
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Evaluation of CSF aSynuclein as a novel prognostic biomarker
Date: December 21, 2021 at 5:02 pm
Request ID: T1817-A
Aim 1: 1) To elucidate the relationship between CSF aSN levels, clinical/cognitive measures and other AD-related CSF biomarkers.
Aim 2: 2) To evaluate the utility of CSF aSN as a prognostic biomarker that is predictive of time until death.
Aim 3:
Aim 4:
Investigator: Timothy Miller
Project Title: ASO-Mediated Approach to Increase Progranulin Protein
Date: December 21, 2021 at 5:02 pm
Request ID: T1909
Aim 1: Measure baseline progranulin protein levels in human GRN patient fibroblasts.
Aim 2: Investigate progranulin protein levels after treatment with progranulin-targeting antisense oligonucleotide.
Aim 3: Assay TDP-43 phosphorylation in human GRN patient fibroblasts.
Aim 4:
Investigator: Colonna
Project Title: digital spatial profiling (DSP) of AD brains
Date: December 21, 2021 at 5:02 pm
Request ID: T1908
Aim 1: To image glia in AD brains compared to controls using a multiple antibodies
Aim 2: To image key activation markers of glia in AD brains compared to controls
Aim 3: To image activated microglia in brains of AD versus AD carrying TREM2 mutations
Aim 4:
Investigator: Jaime Grutzendler
Project Title: Cell biology of PLD3 regulation in Alzheimer disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2023
Aim 1: Superresolution imaging of PLD3 associated lysosomal partners in AD postmortem brain
Aim 2: Characterization of PLD3 effects on AD neuropathology
Aim 3:
Aim 4: